From the Editor's Desk.
作者信息
Flume Patrick A
机构信息
Editor in Chief, Medical University of South Carolina, Charleston, South Carolina, USA.
出版信息
J Cyst Fibros. 2022 Mar;21(2):197-198. doi: 10.1016/j.jcf.2022.03.003.
Abstract
摘要
相似文献
1
From the Editor's Desk.来自编辑台。
J Cyst Fibros. 2022 Mar;21(2):197-198. doi: 10.1016/j.jcf.2022.03.003.
2
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Aug;152(2):257-61. doi: 10.1093/toxsci/kfw113.
3
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Dec;154(2):197-199. doi: 10.1093/toxsci/kfw217.
4
From the Editor's Desk, Editor's Highlights, Letters to the Editor.来自编辑台、编辑要点、读者来信。
Toxicol Sci. 2016 Nov;154(1):1-4. doi: 10.1093/toxsci/kfw206.
5
From the Editor's Desk.来自编辑台。
J Oncol Pract. 2005 Jul;1(2):np.
6
From The Editor's Desk.来自编辑桌前。
Ochsner J. 2000 Jan;2(1):3.
7
From the Editor's desk.来自编辑台。
Lung India. 2010 Jul;27(3):107. doi: 10.4103/0970-2113.68302.
8
From the Editor's desk.来自编辑台。
J Hum Reprod Sci. 2010 May;3(2):61. doi: 10.4103/0974-1208.69330.
9
From the Editor's desk.来自编辑台。
J Hum Reprod Sci. 2010 Sep;3(3):119. doi: 10.4103/0974-1208.74150.
10
From the Editor's Desk.来自编辑台。
Ochsner J. 2011 Spring;11(1):1.
本文引用的文献
1
A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021.年度回顾：2021年的真实世界证据、功能监测与新兴疗法
J Cyst Fibros. 2022 Mar;21(2):191-196. doi: 10.1016/j.jcf.2022.02.014. Epub 2022 Mar 7.
2
Impact of the COVID-19 pandemic: How our response is shaping the future of cystic fibrosis care.新冠疫情的影响：我们的应对措施如何塑造囊性纤维化护理的未来。
J Cyst Fibros. 2021 Dec;20 Suppl 3:1-2. doi: 10.1016/j.jcf.2021.09.002.
3
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network.SARS-CoV-2 对囊性纤维化基金会治疗药物开发网络的影响。
J Cyst Fibros. 2021 Mar;20(2):195-197. doi: 10.1016/j.jcf.2020.12.007. Epub 2020 Dec 15.
4
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.儿童囊性纤维化患者感染 SARS-CoV-2 的临床特征：一项国际观察性研究。
J Cyst Fibros. 2021 Jan;20(1):25-30. doi: 10.1016/j.jcf.2020.11.021. Epub 2020 Dec 3.
5
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.181 名囊性纤维化患者中 SARS-CoV-2 的全球影响。
J Cyst Fibros. 2020 Nov;19(6):868-871. doi: 10.1016/j.jcf.2020.10.003. Epub 2020 Nov 4.
6
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.一份多国报告，旨在描述囊性纤维化患者中 SARS-CoV-2 感染的特征。
J Cyst Fibros. 2020 May;19(3):355-358. doi: 10.1016/j.jcf.2020.04.012. Epub 2020 Apr 25.
7
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.囊性纤维化基金会关于晚期囊性纤维化肺病患者治疗的共识指南。
J Cyst Fibros. 2020 May;19(3):344-354. doi: 10.1016/j.jcf.2020.02.015. Epub 2020 Feb 27.
8
Cystic fibrosis related diabetes: Pathophysiology, screening and diagnosis.囊性纤维化相关性糖尿病：病理生理学、筛查和诊断。
J Cyst Fibros. 2019 Oct;18 Suppl 2:S3-S9. doi: 10.1016/j.jcf.2019.08.016.
9
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.依伐卡托治疗囊性纤维化患者的疾病进展：来自美国和英国国家注册中心的数据。
J Cyst Fibros. 2020 Jan;19(1):68-79. doi: 10.1016/j.jcf.2019.05.015. Epub 2019 Jun 10.
10
Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection.一项测试吸入性一氧化氮治疗耐脓肿分枝杆菌肺病的囊性纤维化患者的初步研究。
J Cyst Fibros. 2020 Mar;19(2):225-231. doi: 10.1016/j.jcf.2019.05.002. Epub 2019 May 23.
Zotero 插件